A randomized, multi-centre, efficacy evaluation of PI-88 in patients with hepatocellular carcinoma after hepatectomy - a phase II study
Phase of Trial: Phase II
Latest Information Update: 01 May 2009
At a glance
- Drugs Muparfostat (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Progen Pharmaceuticals Limited
- 16 Apr 2007 Final results of stage 1 reported in a Progen media release.
- 16 Apr 2007 Status changed from in progress to completed.
- 15 Apr 2007 Results have been presented at EASL 2007.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History